The findings, published in the journal AntiCancer Research, may result in a new treatment option for chemotherapy resistant disease.
Author: Lisa Brown
In an editorial in Annals of Internal Medicine, Tuhina Neogi, MD, PhD, professor of medicine, suggests that it would be reasonable lower uric acid to below the level at which it crystalizes in the blood.
Learn more about wellness related services on campus.
All BUMC faculty, staff and students are encouraged to take the survey Oct. 31-Nov. 4! Access it at www.bumc.bu.edu/transcomm.
Corresponding author Camron Bryant, PhD, assistant professor of Pharmacology and Experimental Therapeutics & Psychiatry believes these findings may lead to new therapeutic treatments which could ultimately save lives and restore healthy eating.
Save the date Jan. 9, 2017 for this Provost Workshop. Open to students, faculty and staff. Program includes short presentations, interactive discussions on future directions for research and collaboration.
Corresponding author Jesse Mez, MD, assistant professor of neurology and associate director of the BU Alzheimer’s Disease & CTE Center Clinical Core, hopes the newly identified genes become targets for AD drug development.
According to corresponding author Hui Feng, MD, PhD, assistant professor of Pharmacology & Experimental Therapeutics, the combination treatment could be an effective strategy to target refractory/relapsed T-cell leukemia.
This workshop features a panel discussion with BUMC senior faculty at various stages of retirement. Open to BUMC faculty.
Scientists can immediately access many of the most frequently used laboratory products.